FDA Approval Obtained, Other Hurdles Remain For Daiichi's Tribenzor
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo obtained U.S. FDA approval for its triple combination fixed-dose hypertension drug Tribenzor on July 23, but the bigger challenges of building a market and winning payer adoption of a product in which two of three components are available as generics remains